Myriad Genetics, Inc. MYGN recently published results from a meta-analysis in the Journal of Clinical Psychopharmacology, stating the superiority of the company’s GeneSight Psychotropic test over ...
Dylan Eyestone submits a cheek swab as part of the GeneSight test he took through his mental healthcare provider, Dawn Johnson. The sample is analyzed in a lab and Johnson receives a report detailing ...
Analysis shows combinatorial approach is more effective than single-gene testing at predicting sertraline metabolism in patients with major depressive disorder SALT LAKE CITY, Feb. 23, 2022 (GLOBE ...
The combinatorial, multi-gene GeneSight test has been found to better predict antidepressant treatment outcomes for patients with depression, and their use of health care resources, than any of the ...
Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the Precision Medicine in Mental Health Care (PRIME) study showed that ...
Depression or anxiety can occur at nearly any age. People aged 65 years or older could experience depression or anxiety for the first time in their lives, or it could be the recurrence of mental ...
SALT LAKE CITY, July 01, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced the launch of a new patient home ...
SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated ...
If you struggle with mental health issues, a simple test can help your clinician if they are considering medication as a course of treatment. (NAPSI)—The holidays have ended, and a new year has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback